Skip to main content
An official website of the United States government
The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Search:
Agenda
Reg Review
ICR
This script is used to control the display of information in this page.
Display additional information by clicking on the following:
All
Brief and OIRA conclusion
Abstract/Justification
Legal Statutes
Rulemaking
FR Notices/Comments
IC List
Burden
Misc.
Common Form Info.
Certification
View Information Collection (IC) List
View Supporting Statement and Other Documents
Please note that the OMB number and expiration date may not have been determined when this Information Collection Request and associated Information Collection forms were submitted to OMB. The approved OMB number and expiration date may be found by clicking on the Notice of Action link below.
View ICR - OIRA Conclusion
OMB Control No:
0910-0435
ICR Reference No:
201110-0910-002
Status:
Historical Active
Previous ICR Reference No:
200908-0910-005
Agency/Subagency:
HHS/FDA
Agency Tracking No:
Title:
Prescription Drug Marketing Act of 1987; Policies, Requirements, and Administrative Procedures
Type of Information Collection:
Extension without change of a currently approved collection
Common Form ICR:
No
Type of Review Request:
Regular
OIRA Conclusion Action:
Approved without change
Conclusion Date:
04/09/2012
Retrieve Notice of Action (NOA)
Date Received in OIRA:
10/05/2011
Terms of Clearance:
OMB notes compliance with the prior terms of clearance. At the time of the next submission, FDA is encouraged to provide descriptive titles for the "information collections" listed in the system. It is not appropropriate to use provision numbers to identify an IC. FDA must also properly identify the nature of the information collection: reporting, recordkeeping, or third-party disclosure. Failure to do so will result in improper submission.
Inventory as of this Action
Requested
Previously Approved
Expiration Date
04/30/2015
36 Months From Approved
04/30/2012
Responses
64,805,294
0
64,805,294
Time Burden (Hours)
2,629,106
0
2,629,106
Cost Burden (Dollars)
0
0
0
Abstract:
This collection is intended to achieve the goals and ensure compliance with the regulations implementing the Prescription Drug Marketing Act of 1987 (PDMA) (Pub. L. 100-293).
Authorizing Statute(s):
None
Citations for New Statutory Requirements:
None
Associated Rulemaking Information
RIN:
Stage of Rulemaking:
Federal Register Citation:
Date:
Not associated with rulemaking
Federal Register Notices & Comments
60-day Notice:
Federal Register Citation:
Citation Date:
76 FR 32362
06/06/2011
30-day Notice:
Federal Register Citation:
Citation Date:
76 FR 60501
09/29/2011
Did the Agency receive public comments on this ICR?
Yes
Number of Information Collection (IC) in this ICR:
26
IC Title
Form No.
Form Name
203.11 Applications for reimportation to provide emergency care
203.23(a) and (b) - Recordkeeping; Credit memo for returned drugs
203.23(c) - Recordkeeping; Proper storage, handling, and shipping conditions for returned drugs
203.30(a)(2) and 203.31(a)(2) - Recordkeeping; Verification of Licensing
203.30(a)(3), (a)(4) and (c) Drug Sample Receipts
203.31(a)(1) and (b) Drug sample requests for samples distributed by means other than mail or a common carrier
203.31(a)(3), (a)(4) and (c) Drug sample receipts for samples distributed by means other than mail or a common carrier
203.31(d)(1) and (d)(2) - Recordkeeping; Inventory Record and Reconciliation report
203.31(d)(4) - Recordkeeping; Discrepancies and Significant Losses
203.31(e) - Recordkeeping; Lists of manufacturers' and distributors' representatives
203.34 - Recordkeeping; Policies and Procedures for administrative systems
203.37(a) - Recordkeeping;Falsification of Drug Sample records
203.37(a) Investigation of falsification of records
203.37(b) - Recordkeeping; Report of investigation of significant loss or known theft
203.37(b) Investigation of significant loss or known theft
203.37(c) Notification of conviction of certain offenses involving drug samples
203.37(d) Notification of the individual responsible for RFI
203.39(d) - Recordkeeping; Samples destroyed or returned by charitable institutions
203.39(e) - Recordkeeping; Samples donated to charitable institutions
203.39(f) - Recordkeeping; Donation and distribution or other disposition of donated drug samples
203.39(g) - Recordkeeping; Inventor and reconciliation of donations to charitable institutions
203.39(g) Preparation of reconciliation report for donated samples
203.50(a) - Third Party Disclosure; Drug Origin Statement
203.50(b) - Recordkeeping; Retention of drug origin statement
203.50(d) - Recordkeeping; List of authorized distributors
203.30(a)(1) and (b) Drug sample requests
ICR Summary of Burden
Total Approved
Previously Approved
Change Due to New Statute
Change Due to Agency Discretion
Change Due to Adjustment in Estimate
Change Due to Potential Violation of the PRA
Annual Number of Responses
64,805,294
64,805,294
0
0
0
0
Annual Time Burden (Hours)
2,629,106
2,629,106
0
0
0
0
Annual Cost Burden (Dollars)
0
0
0
0
0
0
Burden increases because of Program Change due to Agency Discretion:
No
Burden Increase Due to:
Burden decreases because of Program Change due to Agency Discretion:
No
Burden Reduction Due to:
Short Statement:
Annual Cost to Federal Government:
$480,000
Does this IC contain surveys, censuses, or employ statistical methods?
No
Is the Supporting Statement intended to be a Privacy Impact Assessment required by the E-Government Act of 2002?
No
Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]?
No
Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]?
No
Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)?
No
Is this ICR related to the Pandemic Response?
Uncollected
Agency Contact:
Johnny Vilela 301 796-3792 juanmanuel.vilela@fda.hhs.gov
Common Form ICR:
No
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(a) It is necessary for the proper performance of agency functions;
(b) It avoids unnecessary duplication;
(c) It reduces burden on small entities;
(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;
(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;
(f) It indicates the retention periods for recordkeeping requirements;
(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.
(i) It uses effective and efficient statistical survey methodology (if applicable); and
(j) It makes appropriate use of information technology.
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
Certification Date:
10/05/2011
An official website of the United States government
The .gov means it's official.
The site is secure.
